Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
Genelux (NASDAQ: GNLX) has announced its participation in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024. The company's President, CEO and Chairman Thomas Zindrick will engage in discussions moderated by Biotech Equity Research Analyst Emily Bodnar, starting at 11:00 a.m. ET.
The session will focus on the clinical program of Olvi-Vec, including its ongoing:
- Phase 3 registration trial in platinum resistant/refractory ovarian cancer (PRROC)
- Phase 1b/2 trial in small-cell lung cancer (SCLC)
- Phase 2 trial in non-small cell lung cancer (NSCLC)
The event will be accessible through registration, with a replay available for approximately 90 days on the company's IR page.
Genelux (NASDAQ: GNLX) ha annunciato la sua partecipazione a una conversazione virtuale con H.C. Wainwright & Co. il 16 dicembre 2024. Il presidente, CEO e chairman dell'azienda, Thomas Zindrick, parteciperà a discussioni moderate dall'analista di ricerca azionaria nel settore biotecnologico Emily Bodnar, a partire dalle 11:00 ET.
La sessione si concentrerà sul programma clinico di Olvi-Vec, compresi i suoi trial in corso:
- Trial di registrazione di Fase 3 nel cancro ovarico resistente/refrattario al platino (PRROC)
- Trial di Fase 1b/2 nel cancro polmonare a piccole cellule (SCLC)
- Trial di Fase 2 nel cancro polmonare non a piccole cellule (NSCLC)
L'evento sarà accessibile tramite registrazione, con una registrazione disponibile per circa 90 giorni sulla pagina IR dell'azienda.
Genelux (NASDAQ: GNLX) ha anunciado su participación en una charla virtual con H.C. Wainwright & Co. el 16 de diciembre de 2024. El presidente, CEO y presidente de la compañía, Thomas Zindrick, participará en discusiones moderadas por la analista de investigación de equidad biotecnológica Emily Bodnar, comenzando a las 11:00 a.m. ET.
La sesión se centrará en el programa clínico de Olvi-Vec, incluyendo sus ensayos en curso:
- Ensayo de registro de Fase 3 en cáncer de ovario resistente/refractario al platino (PRROC)
- Ensayo de Fase 1b/2 en cáncer de pulmón de células pequeñas (SCLC)
- Ensayo de Fase 2 en cáncer de pulmón no microcítico (NSCLC)
El evento será accesible mediante registro, con una repetición disponible durante aproximadamente 90 días en la página IR de la compañía.
Genelux (NASDAQ: GNLX)는 2024년 12월 16일 H.C. Wainwright & Co.와의 가상 화상 대화에 참여한다고 발표했습니다. 회사의 회장 겸 CEO인 토마스 진드릭이 생물의료 주식 연구 분석가인 에밀리 보드나르의 진행으로 오전 11시 ET부터 논의에 참여할 예정입니다.
이번 세션은 Olvi-Vec의 임상 프로그램에 초점을 맞추며, 현재 진행 중인:
- 백금 저항성/내성 난소암(PRROC) 임상 3상 등록 시험
- 소세포 폐암(SCLC) 임상 1b/2상 시험
- 비소세포 폐암(NSCLC) 임상 2상 시험
이 이벤트는 등록을 통해 참여할 수 있으며, 회사의 IR 페이지에서 약 90일 동안 다시 볼 수 있는 기회가 제공됩니다.
Genelux (NASDAQ: GNLX) a annoncé sa participation à une discussion virtuelle avec H.C. Wainwright & Co. le 16 décembre 2024. Le président, PDG et président de l'entreprise, Thomas Zindrick, participera à des discussions modérées par l'analyste en recherche d'équité biotechnologique Emily Bodnar, à partir de 11h00 ET.
La session se concentrera sur le programme clinique de Olvi-Vec, y compris ses essais en cours :
- Essai d'enregistrement de Phase 3 dans le cancer de l'ovaire résistant/réfractaire au platine (PRROC)
- Essai de Phase 1b/2 dans le cancer du poumon à petites cellules (SCLC)
- Essai de Phase 2 dans le cancer du poumon non à petites cellules (NSCLC)
L'événement sera accessible par inscription, avec une rediffusion disponible pendant environ 90 jours sur la page IR de l'entreprise.
Genelux (NASDAQ: GNLX) hat seine Teilnahme an einem virtuellen Fireside-Chat mit H.C. Wainwright & Co. am 16. Dezember 2024 angekündigt. Der Präsident, CEO und Vorsitzende des Unternehmens, Thomas Zindrick, wird an Diskussionen teilnehmen, die von der Biotech-Aktienanalystin Emily Bodnar moderiert werden und um 11:00 Uhr ET beginnen.
Die Sitzung wird sich auf das klinische Programm von Olvi-Vec konzentrieren, einschließlich seiner laufenden:
- Phase-3-Zulassungsstudie bei platinresistentem/refraktärem Ovarialkarzinom (PRROC)
- Phase-1b/2-Studie bei kleinzelligem Lungenkrebs (SCLC)
- Phase-2-Studie bei nicht-kleinzelligem Lungenkrebs (NSCLC)
Die Veranstaltung wird über eine Registrierung zugänglich sein, mit einer Wiederholung, die ungefähr 90 Tage auf der IR-Seite des Unternehmens verfügbar sein wird.
- None.
- None.
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board will participate in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024.
Biotech Equity Research Analyst, Emily Bodnar, will moderate the HCW@Home session which is scheduled to begin at 11:00 a.m. ET. The discussion will focus on the company’s clinical program of its lead candidate, Olvi-Vec, including its ongoing Phase 3 registration trial in platinum resistant/refractory ovarian cancer (PRROC), Phase 1b/2 trial in small-cell lung cancer (SCLC) and Phase 2 trial in non-small cell lung cancer (NSCLC). To join, please register at https://ct.to/n900Z9K. An archived replay will be available for approximately 90 days following the event on the company’s IR page.
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on Twitter @Genelux_Corp and on LinkedIn.
Investor and Media Contacts
Ankit Bhargava, MD
Allele Communications, LLC
genelux@allelecomms.com
Source: Genelux Corporation
FAQ
What clinical trials will be discussed in Genelux's (GNLX) December 16 fireside chat?
When and where can investors access Genelux's (GNLX) H.C. Wainwright fireside chat?
What cancer types is Genelux (GNLX) targeting with Olvi-Vec?
What is the current development stage of Genelux's (GNLX) lead candidate Olvi-Vec?
